PLoS ONE (Jan 2020)

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.

  • Daniel Camprubí,
  • Alex Almuedo-Riera,
  • Helena Martí-Soler,
  • Alex Soriano,
  • Juan Carlos Hurtado,
  • Carme Subirà,
  • Berta Grau-Pujol,
  • Alejandro Krolewiecki,
  • Jose Muñoz

DOI
https://doi.org/10.1371/journal.pone.0242184
Journal volume & issue
Vol. 15, no. 11
p. e0242184

Abstract

Read online

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.